GB201021103D0 - New compounds for the treatment of neurodegenerative diseases - Google Patents
New compounds for the treatment of neurodegenerative diseasesInfo
- Publication number
- GB201021103D0 GB201021103D0 GBGB1021103.5A GB201021103A GB201021103D0 GB 201021103 D0 GB201021103 D0 GB 201021103D0 GB 201021103 A GB201021103 A GB 201021103A GB 201021103 D0 GB201021103 D0 GB 201021103D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- neurodegenerative diseases
- new compounds
- compounds
- new
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1021103.5A GB201021103D0 (en) | 2010-12-13 | 2010-12-13 | New compounds for the treatment of neurodegenerative diseases |
| ES11805450.1T ES2637288T3 (es) | 2010-12-13 | 2011-12-13 | N-((1H-indol-3-il)-alquil)-4-bencil)benzamida y derivados de N-((1H-pirrolo[2,3-b]piridin-3-il)-alquil)-4-bencil)benzamida como inhibidores de la agregación de alfa-sinucleína para el tratamiento de trastornos neurodegenerativos |
| DK11805450.1T DK2651888T3 (en) | 2010-12-13 | 2011-12-13 | N - ((1H-indol-3-yl) alkyl) -4-benzyl) benzamide and N - ((1H-pyrrolo [2,3-b] pyridin-3-yl) alkyl) -4-benzyl ) benzamide derivatives as alpha-synuclein aggregation inhibitors for the treatment of neurodegenerative diseases |
| CA2819171A CA2819171C (en) | 2010-12-13 | 2011-12-13 | Compounds for the treatment of neurodegenerative diseases |
| JP2013542577A JP6050241B2 (ja) | 2010-12-13 | 2011-12-13 | 神経変性疾患の治療のための新規化合物 |
| HRP20171186TT HRP20171186T1 (hr) | 2010-12-13 | 2011-12-13 | Derivati n-((1h-indol-3-il)-alkil)-4-benzil)benzamida i n-((1h-pirolo[2,3b]piridin-3-il)-alkil)-4-benzil)benzamida kao inhibitori nakupljanja alfa sinukleina za liječenje neurodegenerativnih poremećaja |
| PCT/EP2011/072568 WO2012080221A1 (en) | 2010-12-13 | 2011-12-13 | New compounds for the treatment of neurodegenerative diseases |
| EP11805450.1A EP2651888B1 (en) | 2010-12-13 | 2011-12-13 | N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders |
| SI201131263T SI2651888T1 (sl) | 2010-12-13 | 2011-12-13 | Derivati n-((1h-indol-3-il)-4-benzil)benzamida in n-((1h-pirolo(2,3-b) piridin-3-il)-alkil)-4-benzil)benzamida kot inhibitor agregacije alfa sinukleina, za zdravljenje nevrodegenerativnih motenj |
| CN201180059955.9A CN103261156B (zh) | 2010-12-13 | 2011-12-13 | 用于治疗神经退化性疾病的新化合物 |
| HUE11805450A HUE033277T2 (en) | 2010-12-13 | 2011-12-13 | N - ((1H-Indol-3-yl) alkyl) -4-benzyl) benzamide and N - ((1H-pyrrolo [2,3-b] pyridin-3-yl) alkyl) -4-benzyl ) Benzamide derivatives as alpha-synuclein aggregation inhibitors for the treatment of neurodegenerative disorders |
| US13/993,723 US9266832B2 (en) | 2010-12-13 | 2011-12-13 | Compounds for the treatment of neurodegenerative diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1021103.5A GB201021103D0 (en) | 2010-12-13 | 2010-12-13 | New compounds for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201021103D0 true GB201021103D0 (en) | 2011-01-26 |
Family
ID=43567100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1021103.5A Ceased GB201021103D0 (en) | 2010-12-13 | 2010-12-13 | New compounds for the treatment of neurodegenerative diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9266832B2 (https=) |
| EP (1) | EP2651888B1 (https=) |
| JP (1) | JP6050241B2 (https=) |
| CN (1) | CN103261156B (https=) |
| CA (1) | CA2819171C (https=) |
| DK (1) | DK2651888T3 (https=) |
| ES (1) | ES2637288T3 (https=) |
| GB (1) | GB201021103D0 (https=) |
| HR (1) | HRP20171186T1 (https=) |
| HU (1) | HUE033277T2 (https=) |
| SI (1) | SI2651888T1 (https=) |
| WO (1) | WO2012080221A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201021103D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| GB201021104D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| BR112016015449A8 (pt) * | 2013-12-30 | 2020-06-09 | Lifesci Pharmaceuticals Inc | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos |
| EA032374B1 (ru) * | 2014-01-29 | 2019-05-31 | ЮСиБи БАЙОФАРМА СПРЛ | Гетероарильные амиды в качестве ингибиторов агрегации белков |
| CN104744353B (zh) * | 2015-03-31 | 2017-11-24 | 山东友帮生化科技有限公司 | 2‑氨基‑3‑碘‑5‑氯吡啶的合成方法 |
| CN105130978B (zh) * | 2015-07-22 | 2017-11-21 | 中国人民解放军军事医学科学院基础医学研究所 | 一种化合物及其在帕金森疾病方面的应用 |
| ES2885049T3 (es) | 2015-07-29 | 2021-12-13 | UCB Biopharma SRL | Derivados de bis-heteroarilo como moduladores de la agregación de proteínas |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EA201991650A1 (ru) | 2017-01-06 | 2020-01-20 | Юманити Терапьютикс, Инк. | Способы лечения неврологических расстройств |
| US10913735B2 (en) | 2017-01-26 | 2021-02-09 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
| CN110167937B (zh) | 2017-01-26 | 2022-03-29 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的二环双-杂芳基衍生物 |
| WO2018138085A1 (en) | 2017-01-26 | 2018-08-02 | Ucb Biopharma Sprl | Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation |
| EP3589616A1 (en) | 2017-02-28 | 2020-01-08 | Universitat Autònoma de Barcelona | (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies |
| WO2019025424A1 (en) | 2017-08-04 | 2019-02-07 | Universitat Autonoma De Barcelona | COMPOUNDS FOR TREATING SYNUCLEINOPATHIES |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2019161917A1 (en) | 2018-02-23 | 2019-08-29 | Universitat Autonoma De Barcelona | 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies |
| BR112020019191A2 (pt) | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| JP7640458B2 (ja) | 2018-10-05 | 2025-03-05 | アンナプルナ バイオ インコーポレイテッド | Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物 |
| MX2021008903A (es) | 2019-01-24 | 2021-11-04 | Yumanity Therapeutics Inc | Compuestos y usos de los mismos. |
| WO2020198026A1 (en) * | 2019-03-22 | 2020-10-01 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| CA3148602A1 (en) | 2019-08-02 | 2021-02-11 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to tdp-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3202669A (en) | 1963-11-06 | 1965-08-24 | Upjohn Co | 6-methoxy-1-(3, 4, 5-trimethoxy phenyl)-9h-pyrido [3, 4-b] indole and its acid addition salts |
| IL130169A (en) | 1999-05-27 | 2006-08-20 | Neurim Pharma 1991 | Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them |
| US6306890B1 (en) * | 1999-08-30 | 2001-10-23 | Vanderbilt University | Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors |
| GB9922171D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| CA2411165A1 (en) * | 2000-05-02 | 2002-12-11 | Meiji Seika Kaisha, Ltd. | Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof |
| DOP2002000332A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| CA2517256C (en) * | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| MX2007000150A (es) | 2004-07-01 | 2007-03-30 | Univ California | Inhibicion de moleculas pequenas de la interaccion del domini pdz. |
| US8143257B2 (en) | 2004-11-23 | 2012-03-27 | Ptc Therapeutics, Inc. | Substituted phenols as active agents inhibiting VEGF production |
| WO2007006734A1 (en) * | 2005-07-12 | 2007-01-18 | Bayer Cropscience Sa | New benzoheterocyclylethylbenzamide derivatives |
| EP2149552A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| US20120053165A1 (en) * | 2009-03-03 | 2012-03-01 | Pfizer Inc. | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators |
| GB0910003D0 (en) * | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| ES2360435B1 (es) * | 2009-10-30 | 2012-05-04 | Consejo Superior De Investigaciones Cientificas (Csic) (70%) | Derivados de biss (aralquil) amino y sistemas (6+5)-heteroaromaticos y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer |
| WO2012042621A1 (ja) * | 2010-09-29 | 2012-04-05 | 味の素株式会社 | 塩味増強剤 |
| AU2011329233A1 (en) * | 2010-11-15 | 2013-05-23 | Abbvie Deutschland Gmbh & Co Kg | NAMPT and ROCK inhibitors |
| GB201021104D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| GB201021103D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
-
2010
- 2010-12-13 GB GBGB1021103.5A patent/GB201021103D0/en not_active Ceased
-
2011
- 2011-12-13 EP EP11805450.1A patent/EP2651888B1/en not_active Not-in-force
- 2011-12-13 CA CA2819171A patent/CA2819171C/en active Active
- 2011-12-13 DK DK11805450.1T patent/DK2651888T3/en active
- 2011-12-13 SI SI201131263T patent/SI2651888T1/sl unknown
- 2011-12-13 US US13/993,723 patent/US9266832B2/en active Active
- 2011-12-13 WO PCT/EP2011/072568 patent/WO2012080221A1/en not_active Ceased
- 2011-12-13 HR HRP20171186TT patent/HRP20171186T1/hr unknown
- 2011-12-13 CN CN201180059955.9A patent/CN103261156B/zh not_active Expired - Fee Related
- 2011-12-13 JP JP2013542577A patent/JP6050241B2/ja not_active Expired - Fee Related
- 2011-12-13 HU HUE11805450A patent/HUE033277T2/en unknown
- 2011-12-13 ES ES11805450.1T patent/ES2637288T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9266832B2 (en) | 2016-02-23 |
| JP2013544872A (ja) | 2013-12-19 |
| US20130274260A1 (en) | 2013-10-17 |
| CN103261156B (zh) | 2016-12-28 |
| HRP20171186T1 (hr) | 2017-10-20 |
| HUE033277T2 (en) | 2017-11-28 |
| EP2651888B1 (en) | 2017-05-17 |
| CA2819171C (en) | 2020-02-18 |
| CA2819171A1 (en) | 2012-06-21 |
| EP2651888A1 (en) | 2013-10-23 |
| CN103261156A (zh) | 2013-08-21 |
| ES2637288T3 (es) | 2017-10-11 |
| SI2651888T1 (sl) | 2017-10-30 |
| WO2012080221A1 (en) | 2012-06-21 |
| JP6050241B2 (ja) | 2016-12-21 |
| DK2651888T3 (en) | 2017-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| ZA201402424B (en) | 1- arylcarbonyl -4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| GB0910003D0 (en) | Novel compounds for the treatment of neurodegenerative diseases | |
| IL231835A0 (en) | Pyrrolopyrimidine compounds for cancer treatment | |
| GB2503852B (en) | Compounds for the treatment of neuropsychiatric disorders | |
| EP2611765A4 (en) | METHODS OF TREATING NEURODEGENERATIVE DISEASES | |
| ZA201501390B (en) | Compounds for the treatment of mtor pathway related diseases | |
| ZA201305970B (en) | Arylosulfonami for the treatment of cns diseases | |
| IL275636A (en) | Medical combination for cancer treatment | |
| HUP1100290A2 (en) | Combination compositions for the treatment of proliferative diseases | |
| GB201006167D0 (en) | Compounds for the treatment of metabolic disorders | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| GB201006166D0 (en) | Compounds for the treatment of metabolic disorders | |
| HK1182092A (en) | Arylosulfonamides for the treatment of cns diseases | |
| GB201006163D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004741D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201019482D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004740D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201006164D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004744D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004742D0 (en) | Compounds for the treatment of metabolic disorders | |
| AU2012903365A0 (en) | Compounds for the treatment of mTOR pathway related diseases | |
| GB201119533D0 (en) | Compounds for the treatment of neoplasia | |
| GB201009094D0 (en) | Compounds for the treatment of closridium difficile-associated disease | |
| GB201010671D0 (en) | Compounds for treatment of inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |